

EudraCT number: 2016-004223-23

Protocol NI-0501-06

A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of emapalumab, an anti-interferon gamma (anti-IFN γ) monoclonal antibody, in patients with systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) developing Macrophage Activation Syndrome/secondary HLH (MAS/sHLH)

Sponsor: Swedish Orphan Biovitrum AG

Additional information relating to long term follow-up

All patients who received at least 1 dose of emapalumab in the current study (NI-0501-06) were asked to participate in a separate long-term follow-up study (NI-0501-05), to monitor long-term outcome and safety after emapalumab treatment.